Abstract
Summary
Administration of Benzmalecene alters serum lipids as follows: 1) decreases serum total and esterified cholesterol concentrations; 2) decreases cholesterol and phospholipid content of α (density >1.063 g/ml) and β (density >1.019<1.063 g/ml) lipoproteins; 3) increases serum phospholipid and triglyceride concentrations: 4) increases, both absolutely and relatively, cholesterol and phospholipid content of lipoproteins of density <1.019 g ml; and, 5) decreases C P ratio in whole serum and in α and β lipoproteins. The compound possesses extraordinary lipid-altering properties which warrant further investigation. However, the increase in low density lipoprotein lipids may be an undesirable effect since low density lipoproteins may play a role in atherogenesis.
Get full access to this article
View all access options for this article.
